Cassava Sciences, Inc. (SAVA) News

Cassava Sciences, Inc. (SAVA): $21.72

0.08 (-0.37%)

POWR Rating

Component Grades








Add SAVA to Watchlist
Sign Up

Industry: Biotech




#141 of 360

in industry

Filter SAVA News Items

SAVA News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

SAVA News Highlights

  • For SAVA, its 30 day story count is now at 8.
  • Over the past 19 days, the trend for SAVA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • DEC, DRUG and MD are the most mentioned tickers in articles about SAVA.

Latest SAVA News From Around the Web

Below are the latest news stories about CASSAVA SCIENCES INC that investors may wish to consider to help them evaluate SAVA as an investment opportunity.

3 Growth Stocks Expected to Skyrocket in 2024, According to Wall Street

Wall Street analysts foresee up to 316% upside in three fast-paced companies in the new year.

Yahoo | December 26, 2023

Companies Like Cassava Sciences (NASDAQ:SAVA) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Yahoo | December 20, 2023

Why Cassava Sciences Stock Zoomed 21% Higher This Week

The company has chosen an offbeat way to keep its investors sweet.

Yahoo | December 15, 2023

Cassava Sciences Stock Shows Rising Relative Strength Following 3 Up Days

Cassava Sciences saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, with an upgrade from 79 to 88. The company earns the No. 172 rank among its peers in the Medical-Biomed/Biotech industry group.

Yahoo | December 13, 2023

Why Is Cassava Sciences (SAVA) Stock Up 15% Today?

Although Cassava Sciences’ issuance of warrants presents risks, the underlying Phase 3 trial support boosted SAVA stock.

Josh Enomoto on InvestorPlace | December 12, 2023

Cassava Sciences Announces Dividend Distribution of Warrants to Shareholders

Shareholders of Record Will Receive Warrants to Purchase Shares of Common Stock All Warrants to Be Distributed to Shareholders Free of ChargeWarrants Are Expected to List and Trade on NasdaqWarrant Holders Who Choose to Exercise During an Early Period Will Also Receive an Additional 0.5 of a Common Share Per Warrant AUSTIN, Texas, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) ("Cassava Sciences" or the "Company") today announced a pro rata dividend distribution of warra

Yahoo | December 12, 2023

Why Cassava Sciences Stock Soared Today

Ambitious biotech Cassava Sciences (NASDAQ: SAVA) had a fine Friday on the stock market, with its shares closing more than 17% higher. Cassava, which concentrates its efforts on treatments for Alzheimer's disease, said that it had appointed three new members to its board of directors. Of the trio, two are seasoned veterans in the healthcare industry, and the third has notable experience in cybersecurity and emergency-response management.

Yahoo | December 9, 2023

Cassava Sciences Appoints Three New Members to its Board of Directors

Dr. Nicaise, Mr. Gravier and Mr. Anderson have years of experience in drug development, healthcare M&A and working with the U.S. GovernmentAUSTIN, Texas, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the appointment of three new members to its Board of Directors, effective immediately. Claude Nicaise, MD – Dr. Nicaise has held clinical/regulatory leadership roles that have resulted i

Yahoo | December 7, 2023

7 High-Risk, High-Reward Stocks for the Extreme Contrarian

Although the general concept of stock picks for contrarian investors may be universally appealing, when it comes to the most extreme examples, most investors should probably stay away.

Josh Enomoto on InvestorPlace | November 15, 2023

Cassava Sciences, Inc. (NASDAQ:SAVA): Is Breakeven Near?

With the business potentially at an important milestone, we thought we'd take a closer look at Cassava Sciences, Inc.'s...

Yahoo | November 9, 2023

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!